Education
About Us
Working with TipRanks
Follow Us
Medtronic (MDT)
NYSE:MDT
MDT Analyst Ratings
Moderate Buy
9 Buy
10 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDT Stock 12 Month Forecast
Average Price Target
$110.50
▲(6.93% Upside)
| Highest Price Target$119.00 | Average Price Target$110.50 | Lowest Price Target$90.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
$119
Buy
15.15%
Upside
Reiterated
12/04/25
We have already seen good data for Hugo in two other indications, hernia repair and gyn benign (hysterectomy). MDT recently began a US IDE trial in gyn that includes oncologic cases.
Stifel Nicolaus
$105
Hold
1.61%
Upside
Assigned
12/03/25
Medtronic's Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain ImpactWe rate Medtronic shares Hold. After multiple challenging post-Covid years, Medtronic is now more stable but still a “show-me” story. With the company’s revenue and earnings growth outlook below MedTech peers, new innovations are critical to improve the MDT growth setup. Specifically, the HUGO surgical robotic system, renal denervation hypertension treatment, and new diabetes innovations could be important growth drivers ahead. But, today, it is difficult to gauge when and how these innovations will begin to drive improving MDT performance. In light of MDT's mid-single-digit revenue growth outlook and high-single-digit earnings growth outlook, the stock appears reasonably valued relative to companies similar revenue growth and profitability growth profiles, in our view.
BTIG
―
Hold
―
Reiterated
12/03/25
Medtronic's Strategic Moves and Market Position: Balancing Growth Prospects with Current ValuationWe also would note that given MDT's size and scale, we would not be surprised to see MDT bundle Hugo with other products to health systems in order to place more systems and drive utilization of instrumentation. Given the growing demand for leasing arrangements this may suit MDT well.
Truist Financial
$103→$110
Hold
6.44%
Upside
Reiterated
11/20/25
Barclays
$111
Buy
7.41%
Upside
Reiterated
11/20/25
Citi
$112→$117
Buy
13.22%
Upside
Reiterated
11/19/25
J.P. Morgan
$100→$105
Hold
1.61%
Upside
Reiterated
11/19/25
Robert W. Baird
$103→$109
Hold
5.48%
Upside
Reiterated
11/19/25
Wells Fargo
$100→$114
Buy
10.32%
Upside
Reiterated
11/19/25
Bernstein
$98→$111
Buy
7.41%
Upside
Assigned
11/19/25
UBS
$95→$102
Hold
-1.30%
Downside
Reiterated
11/19/25
Morgan Stanley
$107→$117
Buy
13.22%
Upside
Reiterated
11/19/25
Goldman Sachs
$111
Hold
7.41%
Upside
Upgraded
11/19/25
Analysts Offer Insights on Healthcare Companies: LifeMD (NASDAQ: LFMD) and Medtronic (NYSE: MDT)Medtronic Plc (MDT): 2025 | 4:31PM PST | Research | Equity We upgrade shares of Medtronic (MDT) from Sell to Neutral post 2QFY26 results, as the company's new product momentum picks up and overall P&L metrics take another step in the right direction. Across all metrics, the most notable to us in the accelerated growth in R&D and SG&A, setting the stage for more durable performance, in our view. Simply put, we now see clear evidence of the company's strategy translating into execution. From a valuation perspective, MDT trades at 17.1x our revised CY2026E EPS vs. large cap diversified healthcare comps at ~20.4x (~10x on the low-end to ~29x on the high-end).
William Blair
―
Hold
―
Reiterated
11/19/25
Bank of America Securities
$100→$115
Buy
11.28%
Upside
Reiterated
11/18/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
$119
Buy
15.15%
Upside
Reiterated
12/04/25
We have already seen good data for Hugo in two other indications, hernia repair and gyn benign (hysterectomy). MDT recently began a US IDE trial in gyn that includes oncologic cases.
Stifel Nicolaus
$105
Hold
1.61%
Upside
Assigned
12/03/25
Medtronic's Cautious U.S. Market Entry with HUGO: Hold Rating Amid Uncertain ImpactWe rate Medtronic shares Hold. After multiple challenging post-Covid years, Medtronic is now more stable but still a “show-me” story. With the company’s revenue and earnings growth outlook below MedTech peers, new innovations are critical to improve the MDT growth setup. Specifically, the HUGO surgical robotic system, renal denervation hypertension treatment, and new diabetes innovations could be important growth drivers ahead. But, today, it is difficult to gauge when and how these innovations will begin to drive improving MDT performance. In light of MDT's mid-single-digit revenue growth outlook and high-single-digit earnings growth outlook, the stock appears reasonably valued relative to companies similar revenue growth and profitability growth profiles, in our view.
BTIG
―
Hold
―
Reiterated
12/03/25
Medtronic's Strategic Moves and Market Position: Balancing Growth Prospects with Current ValuationWe also would note that given MDT's size and scale, we would not be surprised to see MDT bundle Hugo with other products to health systems in order to place more systems and drive utilization of instrumentation. Given the growing demand for leasing arrangements this may suit MDT well.
Truist Financial
$103→$110
Hold
6.44%
Upside
Reiterated
11/20/25
Barclays
$111
Buy
7.41%
Upside
Reiterated
11/20/25
Citi
$112→$117
Buy
13.22%
Upside
Reiterated
11/19/25
J.P. Morgan
$100→$105
Hold
1.61%
Upside
Reiterated
11/19/25
Robert W. Baird
$103→$109
Hold
5.48%
Upside
Reiterated
11/19/25
Wells Fargo
$100→$114
Buy
10.32%
Upside
Reiterated
11/19/25
Bernstein
$98→$111
Buy
7.41%
Upside
Assigned
11/19/25
UBS
$95→$102
Hold
-1.30%
Downside
Reiterated
11/19/25
Morgan Stanley
$107→$117
Buy
13.22%
Upside
Reiterated
11/19/25
Goldman Sachs
$111
Hold
7.41%
Upside
Upgraded
11/19/25
Analysts Offer Insights on Healthcare Companies: LifeMD (NASDAQ: LFMD) and Medtronic (NYSE: MDT)Medtronic Plc (MDT): 2025 | 4:31PM PST | Research | Equity We upgrade shares of Medtronic (MDT) from Sell to Neutral post 2QFY26 results, as the company's new product momentum picks up and overall P&L metrics take another step in the right direction. Across all metrics, the most notable to us in the accelerated growth in R&D and SG&A, setting the stage for more durable performance, in our view. Simply put, we now see clear evidence of the company's strategy translating into execution. From a valuation perspective, MDT trades at 17.1x our revised CY2026E EPS vs. large cap diversified healthcare comps at ~20.4x (~10x on the low-end to ~29x on the high-end).
William Blair
―
Hold
―
Reiterated
11/19/25
Bank of America Securities
$100→$115
Buy
11.28%
Upside
Reiterated
11/18/25
Best Analysts Covering Medtronic
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+0.73%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +0.73% per trade.
3 Months
xxx
Success Rate
17/22 ratings generated profit
Average Return
+4.58%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.27% of your transactions generating a profit, with an average return of +4.58% per trade.
1 Year
Success Rate
23/27 ratings generated profit
Average Return
+7.64%
reiterated a buy rating 16 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 85.19% of your transactions generating a profit, with an average return of +7.64% per trade.
2 Years
xxx
Success Rate
26/28 ratings generated profit
Average Return
+14.63%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +14.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDT Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
0
0
0
0
0
Buy
53
51
40
38
32
Hold
22
23
21
18
16
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
76
76
63
57
48
Each month's total comprises the sum of three months' worth of ratings.
MDT Financial Forecast
MDT Stock Forecast FAQ
What is MDT’s average 12-month price target, according to analysts?
Based on analyst ratings, Medtronic’s 12-month average price target is 110.50.
What is MDT’s upside potential, based on the analysts’ average price target?
Medtronic has 6.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDT a Buy, Sell or Hold?
Medtronic has a consensus rating of Moderate Buy which is based on 9 buy ratings, 10 hold ratings and 0 sell ratings.
What is Medtronic’s price target?
The average price target for Medtronic is 110.50. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $119.00 ,the lowest forecast is $90.00. The average price target represents 6.93% Increase from the current price of $103.34.
The highest analyst price target is $119.00 ,the lowest forecast is $90.00. The average price target represents 6.93% Increase from the current price of $103.34.
What do analysts say about Medtronic?
Medtronic’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of MDT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.